See today's BioWorld
To read the full story, subscribe or sign in.

BMS’ Opdivo greenlighted as first immunotherapy for first-line advanced gastric cancer in China

Sep. 1, 2021
By Doris Yu
Bristol Myers Squibb Co.’s Opdivo (nivolumab) is now the first and only immunotherapy for the first-line treatment of advanced gastric cancer in China.
BioWorld Regulatory Cancer China NMPA